November 20, 2026
Business

Third-party pharma manufacturing may rise amid US tariff uncertainty(Soban News)

Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump’s 100% tariff threat looms over patented drugs

​Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump’s 100% tariff threat looms over patented drugs by Soban News (international And National News)

Related posts

Lenskart Share Price LIVE updates: Stocks trade above issue price; should you Buy, Sell or Hold? – Business Standard(Soban News)

News-Soban-Admin

Diabetes Mellitus in TB Lowers Household Risk – EMJ(Soban News)

News-Soban-Admin

Apple’s Foldable iPhone could see a staggered rollout following September launch – Firstpost(Soban News)

News-Soban-Admin

Leave a Comment